10-Q
Quarterly Report
ADIAL PHARMACEUTICALS, INC.
ADIL
NASDAQ
CIK: 1513525
File #: 001-38323
Balance Sheet
27 line items · 2 periods
XBRL
| Item | Jun 30, 2026 | Dec 31, 2025 |
|---|---|---|
ASSETS | ||
Current Assets: | ||
Cash and cash equivalents | 28,712,000 | 5,881,000 |
Prepaid expenses and other current assets | 133,000 | 300,000 |
Total Current Assets | 28,845,000 | 6,181,000 |
Intangible assets, net | 3,000 | 3,000 |
Equity method investment | 241,000 | 490,000 |
Equity Method Investments | 241,000 | 490,000 |
Total Assets | 29,089,000 | 6,674,000 |
LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||
Current Liabilities: | ||
Accounts payable | 2,624,000 | 655,000 |
Accrued expenses | 2,497,000 | 742,000 |
Total Current Liabilities | 5,121,000 | 1,397,000 |
Milestone warrant rights liability | 23,812,000 | — |
Total Liabilities | 28,933,000 | 1,397,000 |
Series A convertible preferred stock, $0.001 par value; 13,000 and 0 shares designated as of June 30, 2026 and December 31, 2025, respectively; 12,930.617 and 0 shares issued and outstanding as of June 30 2026 and December 31, 2025, respectively | 38,533,000 | — |
Stockholders’ (Deficit) Equity | ||
Common Stock, 100,000,000 shares authorized with a par value of $0.001 per share, 2,625,890 and 1,111,010 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 3,000 | 1,000 |
Additional paid in capital | 105,604,000 | 95,248,000 |
Accumulated deficit | (143,984,000) | (89,972,000) |
Total Stockholders’ (Deficit) Equity | (38,377,000) | 5,277,000 |
Accumulated Deficit | (143,984,000) | (89,972,000) |
Additional Paid In Capital | 105,604,000 | 95,248,000 |
Common Stock | 3,000 | 1,000 |
Temporary Equity Series A Convertible Preferred Stock | 38,533,000 | — |
Total Liabilities, Temporary Equity and Stockholders’ (Deficit) Equity | 29,089,000 | 6,674,000 |